Mesoblast Financial Statements From 2010 to 2025
| MEOBF Stock | USD 1.90 0.55 40.74% |
Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as , as well as many indicators such as . Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
Mesoblast |
Mesoblast Company Return On Asset Analysis
Mesoblast's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mesoblast Return On Asset | -0.0688 |
Most of Mesoblast's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mesoblast is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Mesoblast has a Return On Asset of -0.0688. This is 99.21% lower than that of the Healthcare sector and 99.71% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 50.86% lower than that of the firm.
Mesoblast Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mesoblast's current stock value. Our valuation model uses many indicators to compare Mesoblast value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mesoblast competition to find correlations between indicators driving Mesoblast's intrinsic value. More Info.Mesoblast is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mesoblast's earnings, one of the primary drivers of an investment's value.About Mesoblast Financial Statements
Mesoblast stakeholders use historical fundamental indicators, such as Mesoblast's revenue or net income, to determine how well the company is positioned to perform in the future. Although Mesoblast investors may analyze each financial statement separately, they are all interrelated. For example, changes in Mesoblast's assets and liabilities are reflected in the revenues and expenses on Mesoblast's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Mesoblast. Please read more on our technical analysis and fundamental analysis pages.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 77 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Additional Information and Resources on Investing in Mesoblast Pink Sheet
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:Check out the analysis of Mesoblast Correlation against competitors. For more detail on how to invest in Mesoblast Pink Sheet please use our How to Invest in Mesoblast guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.